New study reveals early highly effective therapy significantly reduces disability progression in paediatric MS, offering hope for preserving neurological function.
The Big MS Data network consists of multiple national and international MS registries offering significant advantages for real-world data analysis.
Real-world evidence confirms the benefits of starting treatment in people with MS over 60 years of age, showing ocrelizumab effectively reduces relapses in this group.
People living with MS explain why they love the new Australian MS app designed by people with MS, for people with MS.
MS Australia-supported researchers have developed a suite of free tools allowing MS researchers to apply standard definitions for clinical outcome measures.
MS Australia-supported researchers have investigated the immune effects of vitamin D in people living with MS.
